Close Menu

In the Pipeline's Derek Lowe reminds his readers that interesting Phase II results don't always translate into successful Phase III tests. He points to Antisoma's AS404 and GenVec's TNFerade as examples. Both companies announced that their Phase III trials were being halted after it became clear that neither was going to meet its endpoints.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Two researchers are calling for education for scientists on defending facts.

Researchers were among those who marched in London this weekend to call for another vote on Brexit.

Duke has agreed to pay $112.5 million to settle a lawsuit regarding its handling of data falsified by biologist Erin Potts-Kant. 

In PLOS this week: genetic factors influencing inorganic arsenic metabolism and toxicity, a germline variant in the cell adhesion molecule-coding gene DSCAM, and more.